Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Does Ascorbic Acid Reduce Sympathoexcitation in CHF?

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00550121
Recruitment Status : Completed
First Posted : October 26, 2007
Last Update Posted : October 15, 2008
Sponsor:
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Radboud University

Brief Summary:
In CHF central sympathetic activity is increased. ROS formation seems to play a role in this process. This study analyzes the effect of vitamin C as an antioxidant on central sympathetic activity in CHF

Condition or disease Intervention/treatment Phase
Heart Failure Drug: vitamin C Drug: placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Study Start Date : August 2007
Actual Study Completion Date : April 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin C

Arm Intervention/treatment
Experimental: 1 Drug: vitamin C
Placebo Comparator: 2 Drug: placebo



Primary Outcome Measures :
  1. change in central sympathetic output after vitamin C vs. placebo


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Heart failure of at least New York Heart Association (NYHA) class II
  • Left ventricular ejection fraction (LVEF) <= 40%
  • Age 20-80 years

Exclusion Criteria:

  • Necessity of short-term PCI, CABG or heart transplantation,
  • Chronic disease of the autonomic nervous system,
  • diabetes mellitus,
  • use of tricyclic antidepressant drugs and/or a-adrenergic receptor antagonists.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00550121


Locations
Layout table for location information
Netherlands
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500 HB
Sponsors and Collaborators
Radboud University
ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
Layout table for investigator information
Principal Investigator: Cees J Tack, MD, PhD Radboud University Medical Centre Nijmegen

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00550121     History of Changes
Other Study ID Numbers: CHFVIT
First Posted: October 26, 2007    Key Record Dates
Last Update Posted: October 15, 2008
Last Verified: October 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases